Clinical features and prognosis of spinal diffuse midline gliomas with H3K27M mutation

张培海,孙振兴,刘慧婷,王贵怀
DOI: https://doi.org/10.3760/cma.j.cn112050-20190418-00163
2020-01-01
Abstract:Objective:To explore the clinical features and prognosis of spinal diffuse midline gliomas (SDMGs) with H3K27M mutation. Methods:From May 2015 to October 2017, 12 patients with SDMGs and H3K27M mutation were admitted to Department of Neurosurgery, Beijing Tsinghua Changgung Hospital and enrolled into this study. The clinical features, treatment methods and prognosis were analyzed retrospectively. The patients included 8 males and 4 females and the average age was 28.4±11.9 years(10-53 years). There were 2 cases of dyspnea, 7 cases of limb weakness, 6 cases of paresthesia in body and limbs, and 2 cases of urinary dysfunction. All 12 patients underwent surgical treatment and received temozolomide chemotherapy after surgery without radiotherapy. Survival time was evaluated by out-patient follow-up and telephone follow-up. Results:Among the 12 patients, major resection of tumor was performed in 8 cases and near-total resection in 4 cases. Postoperative histological examination indicated glioblastoma in 7 cases, anaplastic astrocytoma in 3, and anaplastic oligoastrocytoma in 2. Tumor recurrence was reported in all patients post operation. The SDMGs mainly invaded along the spinal cords, and brain metastasis occurred in 2 cases. Twelve patients died within 30 months after operation. The mean ( P25, P75) survival time was 18.0 (5.0, 22.8) months. Conclusions:SDMGs have diverse clinical features, are mostly common in children and young people, and have poor surgical outcome and prognosis.
What problem does this paper attempt to address?